FDA Drug Topics: Research Funding Opportunities to Reduce Preventable Harm
January 28, 2020
FDA
This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety.
The CDER Safe Use Initiative funds research projects aimed at "reducing preventable harm from drugs." This webinar will discuss the types of projects Safe Use funds, the application process, and important dates in the FY2020 funding cycle. Examples of successful projects funded by Safe Use will be provided.
- Core Elements of Anticoagulation Stewardship programs. Available for download at: https://acforum.org/web/education-stewardship.php
- FDA Broad Agency Announcement, FDABAA-20-00123.
- Karter AJ, Warton EM, Lipska KJ, et al. Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. JAMA Intern Med. 2017 Oct 1;177(10):1461-1470. doi: 10.1001/jamainternmed.2017.3844.
- Paul IM, Reynolds KM, Delva-Clark H, et al. Flow Restrictors and Reduction of Accidental Ingestions of Over-the-Counter Medications. Am J Prev Med. 2019 Jun;56(6):e205-e213. doi: 10.1016/j.amepre.2018.12.015. Epub 2019 Apr 17.
- Safe Use Initiative – Extramural Research page.
- Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
- Describe and inform health care providers of recent labeling, policy and regulatory changes which would impact prescribing and medication management to optimize patient care.
- Explain the criteria for applying for funding through the Safe Use Initiative
- Outline the stages of the Broad Agency Announcement (BAA) evaluation process
- Describe qualities that make for a strong research project
This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, and physician assistants.
Lecture 1 January 28, 2020
Time | Topic | Speaker |
---|---|---|
1:00 - 2:00 PM EST | Research Funding Opportunities to Reduce Preventable Harm | Scott Winiecki, MD |
Physicians, physician assistants, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians, physician assistants, and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Faculty
- Winiecki, Scott, MD, medical officer, FDA My spouse received Salary from Mercy Hospital, Baltimore, MD for a role as Employee.
Planning Committee
- Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- Cao, Christian, MPAS, PA-C, Cross-Discipline Safety Advisor, FDA/CDER/OSE/OPE - nothing to disclose
- De Fronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
- Kapoor, Rama, MD, Senior Physician, FDA - nothing to disclose
- Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/DDI - nothing to disclose
- Nguyen-Chu, Thanh, PharmD, Pharmacist, FDA/CDER/OCOMM/DDI - Disclosure not received.
CE Consultation and Accreditation Team
- Lisa Thompson, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration is complimentary; therefore refunds are not applicable.